Bluebird Bio Names Rick Morgan VP, Immunotherapy - Quick Facts

(RTTNews) - bluebird bio Inc. (BLUE) announced that Rick Morgan is joining the company as vice president of Immunotherapy.

Dr. Morgan joins the company from National Cancer Institute or NCI at the National Institutes of Health where he was a Staff Scientist, working on genetically modified T-lymphocytes. He is also an associate investigator on all NCI Surgery Branch Clinical Gene Therapy Protocols. Previously Dr. Morgan was Interim Chief at the Clinical Gene Therapy Branch of the National Human Genome Research Institute.

Morgan was a member of the team that preformed the world's first human gene therapy experiments in 1990 and in 2006 he was the first to report that genetically engineered T cells can cause cancer regression in humans.